CHAPTER 2
REVIEW OF LITERATURE
1. **Tsubouchi Y et al., 2000**, was evaluated the effects of meloxicam on growth of lung cancer cells. They also explained about the way **Meloxicam** inhibit cox-2 and play an important role in pathogenesis and progression of non-small cell lung cancer and it is effectively used in treatment of non-small cell lung cancer [1].

2. **Mayur M. Patel et al., 2011.** Studied about meloxicam which is a selective cox-2 inhibitor and shows its efficacy with pH dependent solubility? **Meloxicam** is a targeted drug and shows and exhibits promising targets in treatment of colorectal cancer [2].

3. **Angela. P G et al., 1998,** has observed the effect of meloxicam in colorectal cancer as targeted drug by conducting *in-vivo* studies which revealed that onset of drug absorption was delayed in coated tablets. **Meloxicam** is a cox-2 inhibitor and effectively delivers the drug to the colon and rectum hence meloxicam is a useful drug in treatment of colorectal cancer. [3].

4. **Mohammed Naseer A et al., 2001, Meloxicam** blocks COX-2 resulting in decreased cell proliferation in desmoids cell cultures and found as an attractive therapeutic target in desmoids tumors and meloxicam also shows marked efficacy compared to other conventional non-selective NSAID’s [4].

5. **Khaggeswar Bheemanapally et al., 2017,** reported the in vitro Anti-Cancer Activity of Rosuvastatin and Ketorolac. Nano-formulations against DDX3. In this paper we report the molecular interaction of Rosuvastatin Calcium (RST) salt with DDX3 by Molecular docking. Molecular dynamics simulation (MDS) using Desmond further confirmed that the RST forms strong intra and inter molecular hydrogen bond network with DDX3 as similar to Ketorolac salt, a known inhibitor of DDX3[5].

6. **Sabindra K. Samal, et al., 2015,** reported about, **Ketorolac** salt is a newly discovered DDX3 inhibitor to treat oral cancer.
References


2. Mayur MP, Avani FA. Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer studied about meloxicam which is a selective cox-2 inhibitor and shows its efficacy with pH dependent solubility. *Drug Deliv.* 2011; 18:281-293.


